Market View 29th March 2023

View on market: Stay Cautious, be with quality business:

Chinese technology shares are set to rally Wednesday as a reorganization of Alibaba provides a bright spot in Asian stocks following a decline in U.S. equities. On the other hand, a slide in technology shares halted a three-day advance in U.S. stocks as investors continued to recalibrate bets on the Federal Reserve’s path forward on interest rates. The Nasdaq 100 slumped 0.5% — paring a March advance to 4.7% — with tech stalwarts from Apple Inc. to Alphabet Inc. among the biggest drags. Meanwhile, U.S. consumers appear to have shrugged off the bank failures, with the latest consumer confidence figures unexpectedly higher in March. Meanwhile, the yield on 10-year treasuries were trading at 3.56%. Crude prices rose to $79-mark, while Bitcoin was hovering around 27,000-level. At 5:52 a.m., the Singapore-traded SGX Nifty, an early indicator of the Nifty 50 Index’s performance in India, was up 0.03% at 16,996. Indian benchmark index Sensex closed 0.07% lower, while the Nifty declined 0.2% as gains in banking and metal stocks were offset by losses in realty, telecom and utilities stocks. The Indian rupee strengthened against the U.S. dollar for the second day in a row, tracking weakness of the foreign unit in overseas markets.

Economic Calendar:

• USD : Pending Home Sales (MoM) (Feb) on 29^th March, 2023
• USD : GDP (QoQ) (Q1) on 30^th March, 2023
• INR : Infrastructure Output (YoY) (Feb) on 31^st March, 2023
• INR : Foreign Debt (USD) (Q4) on 31^st March, 2023

Brokerage Radar:

MS ON ICICI LOMBARD: OW, TP Rs 1400; Management reiterated its guidance of achieving 102% combined ratio over next 2 years; Focus of its digital journey remains on customer engagement & fraud detection; Digitally generated GWP is estimated at Rs 7bn in 9MF23

JPM ON RIL: OW, TP Rs 2960; Investor feedback–There is value but NO catalysts; high capex, lack of Retail disclosures key issues; See range-bound performance as good accumulation opportunity as multiple catalysts play out from CY24 onwards; RIL’s substantial under- performance vs. NIFTY (over past 1 yr, RIL -15% vs. NIFTY -1%) is mostly flows driven (FII ownership is at a 6-yr low, RIL’s P/E de-rating has been in line with NIFTY de-rating) even as underlying biz remains broadly solid

International Markets

U.S & Europe:

Asian markets

ADR Watch:

Commodities & Currency

FIIs & DIIs:

News Update:

Vedanta: The company approved the fifth interim dividend of Rs 20.5 per share for the current fiscal, with a total outgo of Rs 7,621 crore. The record date for the dividend is April 7. Meanwhile, Ajay Goel, the acting CFO of the company, has resigned with effect from April 9.

Tata Power: Company has proposed to set up a high voltage 400 KV line corridor for Mumbai to the state electricity regulator. The proposed transmission line aims to cater to the city’s growing electricity demand by increasing its power capacity.

Larsen & Toubro: The company issued 2 lakh non-convertible debentures to raise Rs 2,000 crore. The bonds will mature on April 28, 2028.

GR Infraprojects: The company received letter of acceptance from East Coast Railway for a project worth Rs 587.59 crore for construction of tunnel work between Adenigarh-Purunakatak and allied works of Khurda-Bolangir new rail line project.

NBCC (India): The company received two work orders, jointly worth Rs 146.39 crore, from SIDBI and Ghani Khan Choudhary Institute of Engineering and Technology.

Jindal Stainless: The company will acquire 49% stake in Indonesia-based nickel pig iron company New Yaking Pte. Ltd. for $157 million (Rs 1,289.8 crore).

JSW Energy: JSW Neo Energy, a wholly owned subsidiary of the company, will acquire additional 12 special purpose vehicles of Mytrah Energy (India) for Rs 1.82 crore.

Aster DM Healthcare: The company acquired additional 1.87% stake in subsidiary Malabar Institute of Medical Sciences for a cash consideration of Rs 18.65 crore, taking its overall shareholding to 76.01%.

Zydus Lifesciences: The company received final approval from U.S. FDA for Loperamide Hydrochloride capsules, the generic version of Imodium capsules.

Source: Moneycontrol, Bloomberg Quint, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL